Understanding the involvement of Nod1 in the development of blood stem cells could greatly improve blood disorder treatments.
List view / Grid view
In the current landscape of drug discovery, lymphoma poses a significant challenge and opportunity. Researchers are fervently exploring novel therapeutic avenues, such as Antibody-Drug Conjugates (ADCs), to address the complexities of lymphoma. ARC-02, a standout candidate, demonstrates enhanced efficacy and tolerability in lymphoma treatment. While eyeing a diverse ADC pipeline,…
Bacteria programmed to paint targets on solid tumours for T cells to see eliminates the need for specific antigens.
A new high-throughput approach has shown how patients whose tumours express CD58 are more likely to respond to CAR T-cell therapy.
CAR T cells have shown incredible promise in the clinic, but there is still room for advancement. One avenue for improvement is through modification of the CAR design. However, given the number of exchangeable domains, testing all variations can present a hurdle. In this article, Dr Sarwish Rafiq, Assistant Professor in…
The new nanotechnology left six of 10 mice with lymphoma tumour-free and was effective in melanoma when combined with existing drugs.
Scientists at the New York University (NYU) Abu Dhabi have used nuclear magnetic resonance (NMR) techniques to determine the structure of a specific nanobody, Nb23. Drug Target Review’s Victoria Rees spoke with lead researcher Professor Gennaro Esposito to find out how their findings could lead to a better understanding of…
Dr Björn Frendeus outlines how the growing biology surrounding the inhibitory Fc receptor FcγRIIb defines a target for improving existing and future antibody treatments.
In pre-clinical studies, researchers showed that cord blood-derived natural killer cells and a bispecific antibody eliminated lymphoma cells.
In this article, we outline three recent studies that have advanced the potential uses of CRISPR in the biomedical field.
By combining natural killer cells with a new molecule called Sialyl-Lewis X, researchers were able to treat lymphoma in mice.
Scientists have developed a novel chimeric antigen receptor (CAR) T-cell therapy to target a variety of human and murine solid-tumour cancer cells.
Researchers have created a method to activate CAR T cells with blue LED light to successfully combat solid tumours in mice.
PROTAC drugs that safely and effectively target leukaemia and lymphoma cells have been developed by researchers.